Eris Lifesciences gains after Q1 PAT climbs 21% YoY to rs 142 cr

Eris Lifesciences added 2.75% to Rs 1,431.90 after the company?s consolidated net profit jumped 20.68% to Rs 142.39 crore in Q1 FY27, compared with Rs 117.99 crore in Q1 FY26.

Revenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter.

Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27.

EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26.

During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter.

Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.

Powered by Capital Market - Live News